The Fifth Circuit reinstated mifepristone's in-person dispensing requirement nationwide on May 1, accepting Louisiana's Medicaid-cost standing theory before the Supreme Court intervened May 4.
A unanimous three-judge panel of the Fifth Circuit Court of Appeals on May 1 granted Louisiana's emergency motion and immediately reinstated the in-person dispensing requirement for mifepristone, effectively overturning the Food and Drug Administration's 2023 Risk Evaluation and Mitigation Strategy rule changes that had permitted mail-order dispensing of the drug [1]. The order took effect nationwide, not merely within Louisiana, and produced immediate disruption for providers and patients who had relied on mail-access protocols established under the FDA's expanded access framework [2].
The case, Louisiana v. FDA, centers on Louisiana's challenge to the FDA's 2023 REMS modifications under the Administrative Procedure Act. Louisiana argued that the FDA's expanded dispensing rules caused the state economic harm by increasing Medicaid costs tied to mifepristone prescriptions, and the panel accepted that theory as sufficient to confer standing [2]. The Fifth Circuit sits in New Orleans and exercised federal jurisdiction over the agency action. Danco Laboratories, the drug's manufacturer, is a respondent in the proceeding alongside the FDA [1].
The panel's standing analysis carries significant weight beyond the immediate abortion-access dispute. By accepting a state's indirect fiscal harm through Medicaid as a cognizable injury in fact, the court opened a pathway for states to challenge federal pharmaceutical approvals and distribution rules with relatively attenuated chains of causation [2]. The nationwide scope of the order, issued on a single state's motion, drew immediate attention from practitioners who track the use of universal injunctions as tools to unwind federal regulatory frameworks [1]. That scope, combined with the speed of the ruling, produced what observers described as system-wide disruption in federally regulated pharmaceutical markets before any appellate briefing cycle could run its course [2].
The Supreme Court intervened on May 4, issuing a temporary order that allowed mail access to the drug to continue while the justices considered the matter further [1]. That administrative stay halted the Fifth Circuit order's practical effect but did not resolve the underlying APA or standing questions. The case now returns to the Supreme Court's docket, where the justices must decide whether to grant a fuller stay, take up the merits, or allow the Fifth Circuit to proceed. A ruling on the scope of state standing to challenge FDA drug approvals would carry consequences well beyond mifepristone.